GB201102189D0 - Materials and methods relating to cardiovascular imaging - Google Patents

Materials and methods relating to cardiovascular imaging

Info

Publication number
GB201102189D0
GB201102189D0 GBGB1102189.6A GB201102189A GB201102189D0 GB 201102189 D0 GB201102189 D0 GB 201102189D0 GB 201102189 A GB201102189 A GB 201102189A GB 201102189 D0 GB201102189 D0 GB 201102189D0
Authority
GB
United Kingdom
Prior art keywords
materials
methods relating
cardiovascular imaging
cardiovascular
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1102189.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Priority to GBGB1102189.6A priority Critical patent/GB201102189D0/en
Publication of GB201102189D0 publication Critical patent/GB201102189D0/en
Priority to PCT/GB2012/000133 priority patent/WO2012107725A1/en
Priority to JP2013553019A priority patent/JP6018585B2/en
Priority to US13/984,522 priority patent/US20140065069A1/en
Priority to EP12706879.9A priority patent/EP2673005A1/en
Priority to CN201280016618.6A priority patent/CN103491983B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1102189.6A 2011-02-08 2011-02-08 Materials and methods relating to cardiovascular imaging Ceased GB201102189D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1102189.6A GB201102189D0 (en) 2011-02-08 2011-02-08 Materials and methods relating to cardiovascular imaging
PCT/GB2012/000133 WO2012107725A1 (en) 2011-02-08 2012-02-08 Materials and methods relating to cardiovascular imaging
JP2013553019A JP6018585B2 (en) 2011-02-08 2012-02-08 Materials and methods related to cardiovascular imaging
US13/984,522 US20140065069A1 (en) 2011-02-08 2012-02-08 Materials and Methods Relating to Cardiovascular Imaging
EP12706879.9A EP2673005A1 (en) 2011-02-08 2012-02-08 Materials and methods relating to cardiovascular imaging
CN201280016618.6A CN103491983B (en) 2011-02-08 2012-02-08 The material relevant to cardiovascular imaging and method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1102189.6A GB201102189D0 (en) 2011-02-08 2011-02-08 Materials and methods relating to cardiovascular imaging

Publications (1)

Publication Number Publication Date
GB201102189D0 true GB201102189D0 (en) 2011-03-23

Family

ID=43836404

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1102189.6A Ceased GB201102189D0 (en) 2011-02-08 2011-02-08 Materials and methods relating to cardiovascular imaging

Country Status (6)

Country Link
US (1) US20140065069A1 (en)
EP (1) EP2673005A1 (en)
JP (1) JP6018585B2 (en)
CN (1) CN103491983B (en)
GB (1) GB201102189D0 (en)
WO (1) WO2012107725A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103290019B (en) * 2013-06-14 2014-03-12 严鹏科 Atherosclerosis targeting aptamer as well as preparation method and application thereof
GB201411907D0 (en) * 2014-07-03 2014-08-20 King S College London Targeted imaging agent
JP6468961B2 (en) * 2015-07-01 2019-02-13 公益財団法人ヒューマンサイエンス振興財団 Double staining kit
CN109876159B (en) * 2019-04-15 2020-06-26 牡丹江医学院 Novel targeted contrast agent and application thereof in cardiovascular disease diagnosis
CN114304053A (en) * 2021-12-10 2022-04-12 广东金石医疗科技服务有限公司 Construction method of rabbit aneurysm model
CN117405870B (en) * 2023-12-15 2024-03-19 北京市心肺血管疾病研究所 Construction of predictive model of unstable plaque phenotype of coronary heart disease patient based on serum lipid metabolite

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
FR2596992B1 (en) * 1986-04-11 1988-12-16 Guerbet Sa GYSOLINIUM-DOTA COMPLEX LYSINE SALT AND ITS APPLICATIONS TO DIAGNOSIS
US4877599A (en) 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
CA1285223C (en) * 1986-11-10 1991-06-25 New England Deaconess Hospital Detection of vascular disease
WO1989010760A1 (en) * 1988-05-02 1989-11-16 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
CA2080493A1 (en) * 1990-05-03 1991-11-04 Robert S. Lees Synthetic peptides for arterial imaging
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AUPP472398A0 (en) * 1998-07-17 1998-08-13 University Of Sydney, The Protease susceptibility II
US20070161003A1 (en) * 2003-09-29 2007-07-12 Morris David W Novel therapeutic targets in cancer
US7575738B2 (en) * 2004-08-13 2009-08-18 General Electric Company Heat shock protein as a targeting agent for endothelium-specific in vivo transduction
US20070014721A1 (en) 2005-06-30 2007-01-18 Harris Thomas D Hydrazide conjugates as imaging agents
DE102007028090A1 (en) * 2007-06-12 2008-12-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Activatable diagnostic and therapeutic compound
JP2011020923A (en) * 2007-11-14 2011-02-03 Katayama Kagaku Kogyo Kk Diagnosis and treatment of arteriosclerosis
EP2206726A1 (en) * 2009-01-08 2010-07-14 Universite Joseph Fourier Non-invasive tools for detecting vulnerable atherosclerotic plaques
US8877157B2 (en) * 2009-07-08 2014-11-04 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents

Also Published As

Publication number Publication date
CN103491983A (en) 2014-01-01
WO2012107725A1 (en) 2012-08-16
JP2014508147A (en) 2014-04-03
JP6018585B2 (en) 2016-11-02
US20140065069A1 (en) 2014-03-06
EP2673005A1 (en) 2013-12-18
CN103491983B (en) 2016-01-13

Similar Documents

Publication Publication Date Title
HUS2100012I1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
IL233051A0 (en) Anti-phf-tau-antibodies and their uses
EP2795570A4 (en) Using photograph to initiate and perform action
EP2736330A4 (en) Compounds and methods
EP2748429A4 (en) Enhanced materials investigation
EP2665726A4 (en) Compositions and methods for cardiovascular disease
EP2747560A4 (en) Compounds and methods
EP2736332A4 (en) Compounds and methods
EP2736329A4 (en) Compounds and methods
IL229844B (en) Anti-psgl-1-antibodies and uses thereof
GB201110783D0 (en) Methods and uses
GB201116774D0 (en) Uses and methods
HK1200486A1 (en) Screening methods and uses thereof
EP2716359A4 (en) Complex and uses thereof
PL2798450T3 (en) Causing elements to be displayed
GB201102189D0 (en) Materials and methods relating to cardiovascular imaging
ZA201308892B (en) Compositions and methods
EP2726110A4 (en) Compositions and methods for metabolic imaging
EP2766357A4 (en) Meso-biliverdin compositions and methods
EP2693879A4 (en) Migrastatins and uses thereof
HK1198587A1 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2-
GB2495390B (en) Improvements in and relating to construction
GB201108490D0 (en) Methods and uses
ME03310B (en) 4 - imidazopyridazin- 1-yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
GB201116340D0 (en) Compositions and methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)